Roche Diabetes Care invites Canadians to join the #UpsideChallenge in support of National Diabetes Awareness Month Français
Initiative Encourages Everyone to See the Upside of Diabetes and Donate to the JDRF By Uploading a Selfie to upsidechallenge.ca
MONTREAL, Nov. 1, 2018 /CNW Telbec/ - To support the 11 million people in Canada living with diabetes and prediabetes, Roche Diabetes Care Canada, who introduced the Accu-Chek® Guide system earlier this year, is announcing the launch of the #UpsideChallenge, a campaign designed to encourage Canadians to show their support for those living with the chronic condition. From November 1st until November 30th, Roche is asking everyone to take the #UpsideChallenge and upload their selfie on UpsideChallenge.ca. The pictures will be flipped upside down, and participants are encouraged to share their story about why the fight against diabetes is important to them. For every uploaded selfie, Roche Diabetes Care will donate $5 to JDRF, a global leader in diabetes research funding and advocacy.
"Whether it's a colleague, friend or family member, chances are that we all know someone living with diabetes. Because of this, we are encouraging everyone to get involved in the #UpsideChallenge and learn more about a condition that can turn a person's world upside down. By sharing a selfie on UpsideChallenge.ca, which will be turned upside down, we want everyone to see the upside and not let diabetes get them down. Every story matters, so please join us in sharing your story and helping people with diabetes think less about their therapy routines while contributing to an important organization," said Marie-Pierre Mathieu, Marketing Director, Roche Diabetes Care Canada.
"For more than 40 years, JDRF has been funding critical type 1 diabetes research that will help improve the lives of people living with diabetes, as we move closer to finding a cure for this often misunderstood disease. We are excited to partner with Accu-Chek during National Diabetes Awareness Month to support this important initiative that encourages people to share their stories raise awareness and funds for Canadians affected by diabetes" says Dave Prowten, President and CEO, JDRF Canada.
For more information about the #UpsideChallenge and to participate, please visit:
www.UpsideChallenge.ca
About the Accu-Chek® Guide system
This year, Roche Diabetes Care launched a revolutionary technology, the Simply Smart Accu-Chek Guide blood glucose meter and its unique spill-resistant SmartPackTM vial. The Accu-Chek Guide system is designed to reduce the hassle of everyday blood glucose testing. With its advanced technology, a wider dosing area, and the pocket-friendly oval shaped SmartPackTM, the Accu-Chek Guide system was specifically created to improve your testing experience – whether you're on your way to work, enjoying yourself outdoors or spending time with your family. Smarter than gravity, the new SmartPackTM vial is designed to hold strips tightly in place, even upside down, making it easier to remove one strip at a time. While the strip ejector keeps things quick, easy and hygienic, the Strip Port Light of the Accu-Chek Guide meter simplifies situations where the test strips must be inserted in the dark or in a low light. Recent studies have shown that 93% of patients find Accu-Chek Guide strips easier and faster to dose1. Moreover, 97% of patients agree that the Accu-Chek Guide meter is extremely easy to use1.
About Roche Diabetes Care
Roche Diabetes Care is pioneering innovative diabetes technologies and services for more than 40 years. Being a global leader in integrated diabetes management, more than 5,000 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target range and experience true relief from the daily therapy routines. Roche Diabetes Care collaborates with caregivers, healthcare providers and payers to optimally manage this complex condition and contribute to sustainable care structures. Under the brand Accu-Chek and in collaboration with partners, Roche Diabetes Care creates value by providing integrated solutions to monitor glucose levels, and track as well as contextualize relevant data points for a successful therapy. By establishing a leading open ecosystem, connecting devices, digital solutions, Roche Diabetes Care will enable optimal personalised diabetes management and thus improve therapy outcomes. Since 2017, mySugr with its world-leading mobile diabetes management app and services is part of Roche Diabetes Care. For more information, please visit: www.accu-chek.com and www.mysugr.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
About JDRF
JDRF is the leading global organization funding type 1 diabetes research. JDRF's goal is to progressively remove the impact of type 1 diabetes from people's lives until we achieve a world without this disease. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit http://www.jdrf.ca/
_____________________________________
1Usability Evaluation Study; Craig Harvey, PhD, PE et al, Journal of Diabetes Science and Technology 2016, data on file.
SOURCE Roche Diabetes Care
Audrey Emanuel, Citoyen, [email protected], 514-297-3112; Geneviève Sorel, Citoyen, [email protected], 514-973-2135
Share this article